Toward Fullerene Immunotherapy with Water-Soluble Paclitaxel-Fullerene Conjugates

dc.contributor.advisorWilson, Lon J.en_US
dc.contributor.committeeMemberBillups, W. Edwarden_US
dc.contributor.committeeMemberMcNew, James A.en_US
dc.contributor.committeeMemberRosenblum, Michael G.en_US
dc.creatorBerger, Christopheren_US
dc.date.accessioned2013-05-13T19:24:05Zen_US
dc.date.accessioned2013-05-13T19:24:13Zen_US
dc.date.available2013-05-13T19:24:05Zen_US
dc.date.available2013-05-13T19:24:13Zen_US
dc.date.created2012-12en_US
dc.date.issued2013-05-13en_US
dc.date.submittedDecember 2012en_US
dc.date.updated2013-05-13T19:24:14Zen_US
dc.description.abstractFor the first time, two distinct, well-characterized water-soluble chemotherapeutic-C60 conjugates have been constructed for targeted drug delivery of paclitaxel to cancer cells. In vitro work was carried out in two stages to determine IC50 values of the conjugates. Primarily, work was carried out on A375m melanoma, T-24 bladder carcinoma, and Hep 3B hepatocellular carcinoma cell lines. In these studies, it was revealed that although the first compound, a paclitaxel-2’-succinate-C60 derivative, experienced a dramatic loss of cytotoxicity in comparison to paclitaxel, the second derivative, utilizing a poly(ethylene glycol) linker, demonstrated over 10× better cytotoxicity than paclitaxel itself. Additional in vitro studies were carried out for the purpose of creating a chemotherapeutic-fullerene-monoclonal antibody immunoconjugate for targeted drug delivery. Building on our previous work, supermolecular forces, instead of covalent chemical bonding were used to associate antibodies with the paclitaxel-2’-succinate-C60 derivative to construct an immunoconjugate. While cytotoxicity was measurable, no discernible advantage was seen by the targeted C60-(ZME-018) immunoconjugate over a MuIgG control, thus leaving room for further refinement of the approach for targeted cancer therapy. In vivo work, using the potent paclitaxel-poly(ethylene glycol)-C60 derivative in a murine model, demonstrated success by producing a similar capacity for tumor-reduction compared to the FDA-approved drug Abraxane®, without the associated weight-loss in animals seen for Abraxane. A major contribution of this work is the progress made toward development of Fullerene Immunotherapy (FIT) and the potential translation of FIT into the clinic. Having demonstrated the potent, improved cytotoxicity of a paclitaxel-C60 conjugate, the next step in the development of FIT is the successful construction of a therapeutic fullerene-antibody immunoconjugate. The results documented in this work have now shifted the onus of FIT from a theoretical concept to a realistic goal awaiting final developmental refinement.en_US
dc.format.mimetypeapplication/pdfen_US
dc.identifier.citationBerger, Christopher. "Toward Fullerene Immunotherapy with Water-Soluble Paclitaxel-Fullerene Conjugates." (2013) Diss., Rice University. <a href="https://hdl.handle.net/1911/71131">https://hdl.handle.net/1911/71131</a>.en_US
dc.identifier.slug123456789/ETD-2012-12-271en_US
dc.identifier.urihttps://hdl.handle.net/1911/71131en_US
dc.language.isoengen_US
dc.rightsCopyright is held by the author, unless otherwise indicated. Permission to reuse, publish, or reproduce the work beyond the bounds of fair use or other exemptions to copyright law must be obtained from the copyright holder.en_US
dc.subjectFullerenesen_US
dc.subjectImmunotherapyen_US
dc.subjectPaclitaxelen_US
dc.titleToward Fullerene Immunotherapy with Water-Soluble Paclitaxel-Fullerene Conjugatesen_US
dc.typeThesisen_US
dc.type.materialTexten_US
thesis.degree.departmentChemistryen_US
thesis.degree.disciplineNatural Sciencesen_US
thesis.degree.grantorRice Universityen_US
thesis.degree.levelDoctoralen_US
thesis.degree.nameDoctor of Philosophyen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
BERGER-THESIS.pdf
Size:
8.49 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.61 KB
Format:
Item-specific license agreed upon to submission
Description: